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Introduction
Epithelial ovarian cancer is a leading cause of mortality re-
lated to cancer among women worldwide [1], and its inci-
dence and mortality rates are increasing in the Republic of 
Korea [2,3]. Although the standard treatment for epithelial 
ovarian cancer had been primary debulking surgery followed 
by platinum-based cytotoxic chemotherapy, a new promis-
ing option of interval debulking surgery (IDS) after neoadju-
vant chemotherapy has been suggested [4]. Data of several 
randomized controlled trials have shown reduction in peri-
operative morbidity and mortality and increase in the possi-
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Objective 
The purpose of this study was to determine the prognostic implications of the pretreatment neutrophil-to-lymphocyte 
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Methods
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Results
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overall survival (OS), but not progression-free survival (PFS). Through multivariate analysis, high pretreatment NLR was 
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were better predictors of PFS than baseline NLR. Patients with increased NLR during chemotherapy showed 
significantly poor PFS, and this change was an independent predictor of PFS.
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Pretreatment NLR and its dynamic change during chemotherapy may be important prognostic factors in patients who 
undergo neoadjuvant chemotherapy.
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bility of a complete resection of tumors during cytoreductive 
surgery [5,6]. Although the initial response to chemotherapy 
is almost 70%, most women with advanced-stage ovarian 
cancer who develop platinum resistance are known to have 
poor prognosis [7,8]. Therefore, it is necessary to develop 
biomarkers for individual evaluation of treatment outcome 
and prognosis.
Since the process of inflammation underlies cancer growth 
and metastasis, several systemic inflammatory response (SIR) 
markers have been studied for their use in prediction of clin-
ical outcomes and prognosis of several cancer types [9-13]. 
Neutrophil-to-lymphocyte ratio (NLR) is one of the recently 
studied SIR markers in gynecologic malignancies including 
advanced epithelial ovarian cancer [14-16]. However, in the 
context of neoadjuvant chemotherapy, evidence for the use 
of NLR markers as an outcome predictor is still insufficient.
Therefore, this study aimed to evaluate the role of pre-
treatment NLR in predicting response to neoadjuvant che-
motherapy and assess the prognostic role of NLR and dy-
namic change of NLR during neoadjuvant chemotherapy in 
advanced epithelial ovarian cancer.
Materials and methods
Patients (n=203) who were diagnosed with advanced epithe-
lial ovarian cancer and received neoadjuvant chemotherapy 
between 2007 and 2015 at Yonsei Cancer Hospital were 
retrospectively identified. The retrospective study protocol of 
this study was approved by our Institutional Review Board 
(registration number: 4-2015-1158).
Retrospective chart review was performed to identify all 
patients who underwent neoadjuvant chemotherapy after 
diagnosis of advanced-stage ovarian cancer. The inclusion cri-
teria were as follows: 1) pathologically proven epithelial ovar-
ian cancer, 2) the International Federation of Gynecology and 
Obstetrics (FIGO) stage III, IV, and 3) received at least 1 cycle of 
neoadjuvant chemotherapy after diagnosis and underwent IDS. 
A total of 197 women met the inclusion criteria. Gynecologic 
oncology team comprising of 5 surgeons conducted all proce-
dures and 2 dedicated in-house pathologists reviewed all micro-
scopic slides based on the World Health Organization criteria.
From medical records and pathologic reports, we collected 
clinical and pathologic data including age, tumor histology, 
American Society of Anesthesiologists (ASA) score, serum 
carbohydrate antigen-125 (CA-125) concentration, FIGO 
stage (revised 2014 version), residual tumor size after IDS, 
total chemotherapy cycles, neutrophil count, lymphocyte 
count, patient’s disease status at last contact, date of last 
visit, and date of disease progression or recurrence. Che-
motherapy response rate was determined according to 
Response Evaluation Criteria in Solid Tumors (RECIST) [17]. 
Furthermore, data of the cause and date of death were 
extracted from death certificates obtained from the Korea 
National Statistical Office.
Taxane plus platinum combination chemotherapy regimens 
were used in neoadjuvant settings. Neoadjuvant chemo-
therapy, IDS, and postoperative adjuvant chemotherapy were 
performed according to the National Comprehensive Cancer 
Network (NCCN) guidelines [4].
All patients were radiologically evaluated after every 3 cy-
cles of neoadjuvant chemotherapy. Moreover, if patients had 
an increased CA-125 during follow-up, radiological evalua-
tion was performed.
Routine blood tests on peripheral vein blood samples were 
performed before the start of every chemotherapy cycle in 
all patients. Pretreatment NLR was determined prior to the 
initiation of neoadjuvant chemotherapy by calculating the 
absolute neutrophil count divided by the lymphocyte count, 
which was obtained as part of the complete blood cell 
count. Post-neoadjuvant chemotherapy NLR was determined 
considering the results of the preoperative blood test, which 
was performed approximately 2 weeks after the last cycle of 
neoadjuvant chemotherapy. Change in NLR was obtained by 
dividing the post-neoadjuvant NLR value by the initial value. 
When this ratio was >1, it was classified as the “increased 
group,” whereas all other cases were classified as the “main-
tained group” [18]. In cases where the patients were given 
granulocyte colony stimulating factor (G-CSF) due to neutro-
penia, the lowest absolute neutrophil count value prior to G-
CSF administration was chosen.
Progression-free survival (PFS) was set as the time interval 
from the beginning of the treatment (neoadjuvant chemo-
therapy) to the progression or recurrence of the disease. 
Overall survival (OS) was set as the time interval from the be-
ginning of the treatment (neoadjuvant chemotherapy) to the 
date of patient death or last visit.
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Results
Of 203 patients who were diagnosed and received neoadju-
vant chemotherapy for ovarian cancer, 197 were suitable for 
analysis. The patient’s baseline characteristics are summarized 
in Table 1.
NLR ranged from 0.64 to 22.8, with a median level of 3.81. 
Receiver operating characteristic (ROC) analysis was used to 
determine the cut-off values of NLR. ROC analysis showed 
that for the NLR value of 3.81, the specificity was 52.9% 
and the sensitivity was 51.2%. A high pretreatment NLR 
was associated with residual disease (RD) (not R0) after IDS 
(P=0.043). Moreover, it was associated with poor response 
rate after neoadjuvant chemotherapy (P=0.069) and plati-
num-resistant recurrence (P=0.074) (Table 2). Kaplan-Meier 
curves showed that, compared with higher NLR, lower base-
line NLR was associated with longer PFS, but this difference 
was not statistically significant (Fig. 1A). Moreover, in the 
univariate analysis, a lower baseline NLR was associated with 
a better OS than a higher baseline NLR (P=0.008) (Fig 1B). In 
the multivariate analysis, when adjusted for age, histology, 
ASA score, serum CA-125 levels, FIGO stage, residual dis-
ease, and total cycles of chemotherapy, a lower baseline NLR 
was an independent prognostic factor for OS (hazard ratio 
[HR], 1.89; 95% confidence interval [CI], 1.11–3.24) (Table 3).
Dynamic change in NLR during neoadjuvant chemotherapy 
showed prognostic value for PFS in our cohort. NLR changes 
ranged from 0.02 to 7.14. The area under ROC curve for NLR 
changes (0.632; 95% CI, 0.548–0.715) was higher than the 
area under ROC curve for pretreatment NLR (0.544; 95% CI, 
0.456–0.632) for predicting recurrence. Kaplan-Meier curves 
showed significantly poor PFS in patients with increased NLR 
during neoadjuvant chemotherapy (P=0.006; Fig. 2A). In the 
multivariate analysis, change in NLR was an independent 
prognostic factor for PFS (HR, 2.07; 95% CI, 1.32–3.25; 
Table 3). For OS, trends were observed, but there was no sig-
nificant difference between the 2 groups (Fig. 2B).
Analysis of NLR in patients who showed NLR changes during 
chemotherapy (low pretreatment NLR with maintained NLR, 
low pretreatment NLR with increased NLR, high pretreatment 
NLR with maintained NLR, and high pretreatment NLR with 
increased NLR) showed that patients with high pretreatment 
NLR with increased NLR during neoadjuvant chemotherapy 
had the shortest PFS and OS (HR, 2.12; 95% CI, 1.08–4.15 
and HR, 2.43; 95% CI, 1.00–5.88, respectively; Fig. 3).
Discussion
In this study, we investigated the predictive and prognostic 
value of NLR for ovarian cancer patients undergoing neoad-
juvant chemotherapy. Results showed that high pretreatment 
NLR was not only associated with RD after IDS, poor response 
to neoadjuvant chemotherapy, and platinum resistant recur-
rence, but also served as a statistically significant independent 
Table 1. Baseline characteristics
Characteristics Value
Age (yr) 57 (27–80)
Histology
HGSC 180 (91.4)
Non-HGSC 17 (8.6)
ASA score
1 51 (26.3)
2 92 (47.4)
3 50 (25.8)
4 1 (0.5)
CA-125 (U/mL) 1,825.7 (44.3–30,000)
FIGO stage
IIIB 7 (3.6)
IIIC 45 (22.8)
IVA 89 (45.2)
IVB 56 (28.4)
RD after IDS (cm)
NGR 72 (36.6)
≤0.5 63 (32.0)
≤1 27 (13.7)
≤2 5 (2.5)
>2 8 (4.1)
Unknown 22 (11.2)
Total cycles of chemotherapy
<6 8 (4.1)
≥6 189 (95.9)
Regimen of neoadjuvant chemotherapy
Taxane+carboplatin 197 (100.0)
Data are shown as median (range) or number (%).
HGSC, high-grade serous carcinoma; ASA, American Society of An-
esthesiologists; CA-125, carbohydrate antigen-125; FIGO, Interna-
tional Federation of Gynecology and Obstetrics; RD, residual disease; 
IDS, interval debulking surgery; NGR, no gross residual disease.
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Table 2. Comparison between the high neutrophil-to-lymphocyte ratio and low NLR groups
Characteristics Low NLR group High NLR group P-value
Age (yr) 0.643
 ≤65 67 (72.0) 72 (76.6)
 >65 26 (28.0) 22 (23.4)
ASA score 0.476
 ≤2 71 (76.3) 69 (73.4)
 ≥3 22 (23.7) 25 (26.6)
CA-125 (U/mL) 0.994
 ≤2,000 48 (51.6) 49 (52.1)
 >2,000 43 (45.7) 44 (46.8)
Missing 2 (0.7) 1 (1.1)
RD after IDS 0.043
R0 41 (44.1) 28 (29.8)
Not R0 52 (55.9) 66 (70.2)
No. of CRS 0.213
1 2 (2.1) 6 (6.3)
2 36 (38.7) 37 (39.4)
3 32 (34.4) 24 (25.5)
Missing 23 (24.7) 27 (28.8)
Platinum resistant recur 0.074
No 74 (79.6) 64 (68.1)
Platinum resistant recur 19 (20.4) 30 (31.9)
RR (by imaging study) 0.069
CR+PR 80 (86.0) 75 (79.8)
SD+PD 8 (8.6) 17 (18.1)
Missing 5 (5.4) 2 (2.1)
Data are shown as number (%).
NLR, neutrophil-to-lymphocyte ratio; ASA, American Society of Anesthesiologists; CA-125, carbohydrate antigen-125; RD, residual disease; 
IDS, interval debulking surgery; CRS, cytoreductive surgery; RR, response rate; CR, complete response; PR, partial response; SD, stable disease; 
PD, progressive disease.
Fig. 1. Kaplan-Meier curve of (A) (P=0.725) progression-free survival and (B) (P=0.008) overall survival stratified by neutrophil-to-lym-
phocyte ratio (NLR) level. 
A  B
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predictor of OS. Furthermore, the dynamic change in NLR, 
defined as the ratio of preoperative NLR to pretreatment NLR, 
was a valuable prognostic marker of recurrence and PFS.
Neutrophils and lymphocytes are key players in tumor im-
munology [19]. Neutrophils release cytotoxic mediators in-
cluding reactive oxygen species and neutrophil elastase that 
inflict damage to cellular DNA and promote cancerassociated 
angiogenesis [20,21]. Leukocytopenia inhibits neoplastic cell 
apoptosis [22]. In recent years, neutrophil count, lymphocyte 
count, and their combinations (NLR) have been repeatedly 
reported to have prognostic value in various cancers such as 
bladder, pancreatic, breast, and colorectal cancers [10-13]. Re-
ports on the prognostic value of NLR dynamic changes have 
also been published for other cancers [18,23].
However, the studies on NLR in ovarian cancer setting are 
Table 3. Multivariate analysis for progression-free survival and 
overall survival
Variables PFS (95% CI) OS (95% CI)
Pretreatment NLR
<3.81 1.00 1.00
>3.81 1.25 (0.86–1.83) 1.89 (1.11–3.24)
NLR change
Maintained 1.00 1.00
Increased 2.07 (1.32–3.25) 1.56 (0.84–2.91)
Adjustment for age, histology, American Society of Anesthesiolo-
gists, carbohydrate antigen-125, International Federation of Gy-
necology and Obstetrics stage, residual disease, and total cycles of 
chemotherapy.
PFS, progression-free survival; CI, confidence interval; OS, overall sur-
vival; NLR, neutrophil-to-lymphocyte ratio.
Fig. 2. Kaplan-Meier curve of (A) (P=0.006) progression-free survival and (B) (P=0.320) overall survival stratified by change of neutrophil-
to-lymphocyte ratio (NLR).
Fig. 3. Kaplan-Meier curve of (A) progression-free survival and (B) overall survival according to pretreatment neutrophil-to-lymphocyte 
ratio (NLR) and dynamic change in NLR. LM, low pretreatment/maintained during chemotherapy; LI, low pretreatment/increased during 
chemotherapy; HM, high pretreatment/maintained during chemotherapy; HI, high pretreatment/increased during chemotherapy.
A  B
A  B
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still at primitive stage. NLR levels of epithelial ovarian cancer 
patients were compared with healthy controls including be-
nign ovarian tumors in a previous study [24]. They suggested 
that the increased NLR level might serve as a cost-effective 
method of differentiating ovarian cancers from benign ovar-
ian cysts. Furthermore, Williams et al. [25] suggested that 
high NLR levels were associated with an advanced FIGO stage, 
greater tumor grade, and more extensive ascites in ovarian 
cancer patients. Several studies on patients who underwent 
primary debulking surgery for epithelial ovarian cancer have 
reported the prognostic significance of preoperative NLR. For 
example, Feng et al. [15] suggested that preoperative NLR 
has high predictive and prognostic significance in high-grade 
serous ovarian cancer patients. Miao et al. [14] suggested 
that preoperative NLR is an independent prognostic marker 
for platinum-based chemotherapy after primary debulking 
surgery.
To our knowledge, this is the first report that describes 
the prognostic significance of pretreatment NLR level and its 
dynamic changes in advanced-stage ovarian cancer patients 
undergoing neoadjuvant therapy.
There are limitations to this analysis. First, this is a retrospec-
tive study of previously obtained medical records. Although 
we utilized data obtained from the electronic medical records, 
biases such as selection bias may exist. Further studies with 
larger sample size and prospective research design are recom-
mended. Second, there is no consensus on the exact cut-off 
value for NLR, although previous studies have reported the 
value of NLR for the prognosis of ovarian cancer [14,15,25-
30]. In this study, NLR cut-off value of 3.81 was selected using 
ROC analysis using the procedure reported in other studies 
[14,24,29]. Some other previous studies used a median level 
of NLR to determine the cut-off value [15,25-28,30]. This lack 
of consensus on the cut-off makes NLR difficult to be used 
in daily clinical practice. Thus, developing a nomogram of 
NLR will be beneficial. Third, NLR is a nonspecific marker of 
inflammation. Therefore, another systemic disease could have 
affected the NLR value.
In conclusion, our preliminary analysis showed the possibil-
ity of utilizing NLR levels as prognostic markers in advanced-
stage ovarian cancer patients who will undergo neoadjuvant 
chemotherapy. In addition, considering dynamic changes in 
NLR during chemotherapy might help to estimate a more ac-
curate prognosis in advanced-stage ovarian cancer. NLR can 
be easily obtained from routine blood tests, thus providing 
opportunities for future research as a convenient and cost-
effective biomarker.
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